Navelbine (Vinorelbine)

Vinorelbine, the active ingredient in Navelbine, is a Vinca alkaloid presented as a capsule for oral use. It is employed in the treatment of certain solid tumours, notably non‑small cell lung cancer and breast cancer, in adult oncology patients and may be part of combination chemotherapy regimens.

GNH USA supplies Navelbine as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide with a focus on quality assurance, regulatory compliance and reliable global logistics. Our network ensures timely delivery to clinical sites across Europe, Asia and the Americas.

Vinorelbine (Navelbine) is a Vinca alkaloid used in oncology to inhibit cell division in solid tumours.

Non‑small cell lung cancer: Improves disease control and may extend survival when used as part of a chemotherapy regimen. Breast cancer: Provides antitumour activity, particularly in metastatic or locally advanced disease, often in combination with other agents.

Vinorelbine may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Neutropenia: reduced white blood cell count, increasing infection risk. - Nausea and vomiting: gastrointestinal upset. - Fatigue: general tiredness.

Serious or Rare Side Effects: - Febrile neutropenia: severe neutropenia with fever. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Peripheral neuropathy: nerve damage causing tingling or pain.

When prescribing Vinorelbine, clinicians should observe several safety measures. - Monitor blood counts: regular CBC to detect neutropenia or anemia. - Assess liver function: adjust if hepatic impairment is present. - Avoid concurrent myelosuppressive agents: increased risk of bone‑marrow toxicity. - Use anti‑emetics prophylactically: to reduce nausea and vomiting. - Pregnancy and lactation: contraindicated or unknown; avoid use in pregnant or breastfeeding women. - Store at ambient temperature: keep capsules in the original container, protect from moisture and light.

Vinorelbine can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase vinorelbine exposure. - Concurrent use with other myelosuppressive chemotherapy: heightened risk of severe neutropenia. - Live vaccines: immunosuppression may reduce vaccine efficacy.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce effectiveness. - Anticoagulants (e.g., warfarin): potential for altered bleeding risk. - Drugs causing QT prolongation: additive cardiac risk.